Background: In spite of their importance as arthropod predators, spiders have received little attention in the risk assessment of pesticides. In addition, research has mainly focused on a few species commonly found in agricultural habitats. Spiders living in more natural ecosystems may also be exposed to and affected by pesticides, including insecticides. However, their sensitivity and factors driving possible variations in sensitivity between spider taxa are largely unknown. To fill this gap, we quantified the sensitivity of 28 spider species from a wide range of European ecosystems to lambda-cyhalothrin in an acute exposure scenario.
Results: Sensitivity varied among the tested populations by a factor of 30. Strong differences in sensitivity were observed between families, but also between genera within the Lycosidae. Apart from the variation explained by the phylogeny, spiders from boreal and polar climates were more sensitive than spiders from warmer areas. Overall, the median lethal concentration (LC ) of 85% of species was below the recommended application rate of lambda-cyhalothrin (75 ng a.i. cm ).
Conclusion: Our study underlines the high sensitivity of spiders to lambda-cyhalothrin, which can lead to unintended negative effects on pest suppression in areas treated with this insecticide. The strong differences observed between families and genera indicate that the functional composition of spider communities would change in affected areas. Overall, the variation in spider sensitivity suggests that multispecies investigations should be more widely considered in pesticide risk assessment. © 2023 The Authors. Pest Management Science published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ps.7818 | DOI Listing |
Alzheimers Dement
December 2024
University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA.
Background: Pharmacoepidemiologic studies assessing drug effectiveness for Alzheimer's disease and related dementias (ADRD) are increasingly popular given the critical need for effective therapies for ADRD. To meet the urgent need for robust dementia ascertainment from real-world data, we aimed to develop a novel algorithm for identifying incident and prevalent dementia in claims.
Method: We developed algorithm candidates by different timing/frequency of dementia diagnosis/treatment to identify dementia from inpatient/outpatient/prescription claims for 6,515 and 3,997 participants from Visits 5 (2011-2013; mean age 75.
Background: The therapeutic management of dementia with Lewy bodies (LBD) is a challenge given the high sensitivity to drugs in this disease. This is particularly sensitive with regard to the management of parkinsonism. In particular, treatment of motor symptoms with levodopa or dopaminergic agonists poses a risk of worsening cognitive and behavioral symptoms.
View Article and Find Full Text PDFBackground: Clinical outcome assessments (COAs) are an important part of clinical trials to measure what is meaningful to patients and caregivers. This study aimed to examine trends in Alzheimer's Disease (AD) COAs used in clinical trials, given the FDA's recent emphasis on patient-focused drug development and early AD.
Method: ClinicalTrials.
Background: Participant retention is a key determinant for a successful clinical trial. In Alzheimer's disease (AD) trials, participants are typically required to enroll with a study partner, which adds barriers to retention. Previous analyses of North American trial data found that most study partners were spouses and that such dyads had higher study completion rates than other study partner types.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
Background: The first disease-modifying treatments (DMTs) for Alzheimer's disease (AD) have been approved in the USA, marking profound changes in AD-diagnosis and treatment. This will bring new challenges in terms of clinician-patient communication. We aimed to collect the perspectives of memory clinic professionals regarding the most important topics to address and what (tools) would support professionals and their patients and care partners to engage in a meaningful conversation on whether (or not) to initiate treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!